VIVOS THERAPEUTICS INC

Company Overview

Vivos Therapeutics Inc. is a Healthcare company in the Medical Devices industry that focuses on non-surgical treatment of obstructive sleep apnea, snoring, and related dentofacial issues through its proprietary Vivos Method. Its business is shifting from a legacy dentist-training model toward a provider- and sleep-center-focused distribution strategy, including acquisitions and management agreements tied to sleep clinics and DSO/MSO structures. Recent filings show revenue growth driven by sleep testing services and treatment-center activity, but also highlight significant operating losses, tight liquidity, and going-concern risk. The company’s operations depend heavily on FDA clearances, reimbursement access, provider recruitment, and successful integration of new clinical locations.

Executive Compensation Practices

For a company like Vivos, executive compensation is likely to be heavily influenced by growth milestones rather than near-term profitability, since the business is still scaling and reported losses remain substantial. In the Healthcare / Medical Devices space, executives are often compensated with a mix of cash salary, annual bonuses, and equity awards tied to revenue growth, regulatory progress, product adoption, and strategic execution. Based on the filings, compensation incentives would likely be aligned to metrics such as sleep-center onboarding, treatment-case starts, gross margin stability, cash preservation, FDA/regulatory achievements, and successful acquisition integration. Because Vivos is capital constrained and explicitly raised going-concern concerns, equity-based pay and milestone-based awards may be especially important in retaining management while limiting cash burn.

Insider Trading Considerations

Insider trading patterns at Vivos may be strongly affected by financing needs, acquisition activity, and regulatory catalysts. Companies in the Medical Devices industry often see insider buying or selling around FDA milestones, reimbursement developments, clinical study results, and M&A events, all of which are relevant here given Vivos’s reliance on FDA-cleared products and ongoing clinical research. The company’s tight liquidity, Nasdaq listing risk, and repeated equity/debt financings can also create periods where insiders may be restricted from trading or may prefer trading in conjunction with scheduled capital raises and material announcements. For researchers and traders, insider transactions should be viewed in the context of whether management is signaling confidence in the new sleep-center model, additional financing prospects, or upcoming regulatory and clinical-readout events.